A Study of Ipilimumab, Cabozantinib and Nivolumab in Rare Genitourinary Tumors (A031702)
A Study of Ipilimumab, Cabozantinib and Nivolumab in Rare Genitourinary Tumors (A031702)
Trial Category:
Genitourinary
Phase
II
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
